Below are six illustrative examples of ASX-listed biotech companies (excluding BARD1, IMM, or GTG which were discussed earlier) that undertook share consolidations and, over the ensuing five-year period, saw an overall increase in share price or market capitalisation. Data are drawn from publicly available ASX announcements, company annual reports, and historical price data from resources such as Market Index and ASX releases. (All figures are approximate and indicative only; please verify with up-to-date sources for precise numbers.)
Avita Medical (ASX: AVH)
Consolidation Date & Ratio: 30 April 2019, 1-for-100 share consolidation
Pre- & Post-Consolidation Share Price
Pre-consolidation: ~A$0.08
Post-consolidation (adjusted): ~A$8.00
Market Capitalisation
Before: ~A$170 million
After (immediate post-consolidation): ~A$180 million (minor variance due to fractional rounding and market perception)
Five years later (approx.): Exceeded A$1.0 billion at times, supported by US market expansion of its RECELL® system
Key Factors Behind Positive Response
Improved Investor Perception: The higher post-consolidation share price was seen as more aligned with institutional investment thresholds.
Enhanced Liquidity & Visibility: Subsequent NASDAQ listing and increased international investor engagement.
Strategic Actions: Strong product commercialisation in the US, supported by positive clinical data and growing revenues.
Polynovo Limited (ASX: PNV)
Consolidation Date & Ratio: November 2015, 1-for-25 share consolidation
Pre- & Post-Consolidation Share Price
Pre-consolidation: ~A$0.03
Post-consolidation (adjusted): ~A$0.75
Market Capitalisation
Before: ~A$20 million
After (immediate post-consolidation): ~A$22 million
Five years later (approx.): Surpassed A$1.0 billion in 2020/21 with the success of its NovoSorb™ wound treatment product
Key Factors Behind Positive Response
Product Adoption: Accelerating sales of NovoSorb™ BTM (Biodegradable Temporising Matrix).
Stronger Market Position: New capital raisings and partnerships boosted investor confidence.
Institutional Interest: The higher share price post-consolidation enhanced appeal to larger funds.
Clinuvel Pharmaceuticals (ASX: CUV)
Consolidation Date & Ratio: 20 November 2014, 1-for-10 share consolidation
Pre- & Post-Consolidation Share Price
Pre-consolidation: ~A$0.50
Post-consolidation (adjusted): ~A$5.00
Market Capitalisation
Before: ~A$180 million
After (immediate post-consolidation): ~A$200 million
Five years later (approx.): Surpassed A$1.5 billion, driven by increasing global sales of SCENESSE®
Key Factors Behind Positive Response
Regulatory Milestones: FDA approval of SCENESSE® for treating erythropoietic protoporphyria.
Increasing Revenue Stream: European and US market uptake.
Heightened Profile: A higher share price often garners more analyst coverage and institutional visibility.
Neuren Pharmaceuticals (ASX: NEU)
Consolidation Date & Ratio: 29 November 2012, 1-for-20 share consolidation
Pre- & Post-Consolidation Share Price
Pre-consolidation: ~A$0.06
Post-consolidation (adjusted): ~A$1.20
Market Capitalisation
Before: ~A$35 million
After (immediate post-consolidation): ~A$36–40 million range
Five years later (approx.): Exceeded A$500 million (notably in 2017–2018) on optimism around trofinetide and other R&D assets
Key Factors Behind Positive Response
Pipeline Progress: Advancements in clinical trials for Rett syndrome and other neurological conditions.
Strategic Partnerships: Collaborations with North American and European biotech firms.
Reduced Volatility: Consolidation helped reduce extreme share price fluctuations, improving credibility.
PYC Therapeutics (ASX: PYC) (formerly Phylogica)
Consolidation Date & Ratio: 8 September 2016, 1-for-15 share consolidation
Pre- & Post-Consolidation Share Price
Pre-consolidation: ~A$0.015
Post-consolidation (adjusted): ~A$0.225
Market Capitalisation
Before: ~A$40 million
After (immediate post-consolidation): ~A$42 million
Five years later (approx.): Surpassed A$300 million at times, driven by genetic therapy platform developments
Key Factors Behind Positive Response
Pipeline Expansion: Focus on RNA therapies and key licensing deals.
Investor Relations: The consolidation made the company’s shares appear less “penny stock”-like and more attractive.
Strategic Funding: Capital raisings at improved valuations, accelerating R&D.
ImpediMed Limited (ASX: IPD)
Consolidation Date & Ratio: 13 October 2014, 1-for-5 share consolidation
Pre- & Post-Consolidation Share Price
Pre-consolidation: ~A$0.20
Post-consolidation (adjusted): ~A$1.00
Market Capitalisation
Before: ~A$60 million
After (immediate post-consolidation): ~A$62 million
Five years later (approx.): Market cap intermittently exceeded A$250 million on positive clinical adoption of SOZO®
Key Factors Behind Positive Response
Commercial Rollouts: Increased adoption of the company’s L-Dex and SOZO® systems for lymphoedema and heart failure.
Broader Global Footprint: Partnerships and strong US clinical traction.
Institutional Engagement: The higher share price enticed new classes of investors.
Observations and Common Themes
Investor Perception: Many smaller biotech firms trade at fractions of a cent; consolidations often help remove the ‘penny stock’ stigma.
Liquidity & Institutional Appeal: A higher share price can meet minimum investment thresholds for certain institutional investors and index inclusions.
Strategic Corporate Actions: Successful product launches, FDA approvals, and strategic partnerships amplify the positive effect of a consolidation.
Post-Consolidation Volatility: While consolidations can improve share structure, real long-term gains typically rely on company fundamentals—e.g., clinical success or product sales.
Disclaimer: All numerical figures (share prices, market capitalisations) are approximations meant as a guide. For the most accurate and up-to-date figures, refer to official ASX releases, company annual reports, and reputable financial data providers (e.g., Market Index, brokers’ historical data services).
Add to My Watchlist
What is My Watchlist?
